Adderall XR (amphetamine)

[Guest guest]

Adderall XR (amphetamine)

Audience: Neuropsychiatric and other healthcare professionals FDA

issued a

Public Health Advisory to notify healthcare professionals that Health

Canada, the Canadian drug regulatory agency, has suspended the sale

of

Adderall XR in the Canadian market. Adderall XR is a controlled

release

amphetamine used to treat patients with Attention Deficit

Hyperactivity

Disorder (ADHD). The Canadian action was based on U.S. post-marketing

reports of sudden deaths in pediatric patients. FDA is continuing to

evaluate these and other post-marketing reports of serious adverse

events in

children, adolescents, and adults being treated with Adderall and

related

products. Adderall XR is approved in the United States for the

treatment of

adults and pediatric patients 6-12 years old with ADHD, and

Adderall, the

immediate release formulation of the drug, is approved for pediatric

patients with ADHD.